BUZZ-UniQure extends eye-watering rally ahead of planned $200 mln share offering
U.S.-listed shares of Dutch drugmaker UniQure surged approximately 248% to $47.50 following positive results from an early-to-mid-stage trial of its experimental gene therapy for Huntington's disease. The company plans a $200 million share offering and currently has about 54.9 million shares outstanding, with a market cap of around $2.6 billion. Short interest in UniQure shares has nearly tripled since the beginning of 2025, with about 8.3 million shares sold short as of September 25, representing approximately 16% of the public float.
U.S.-listed shares of Dutch drugmaker U
up ~248% at $47.50 after co said its experimental gene therapy significantly Huntington’s disease progression in an early-to-mid-stage trial
It also announced securing QURE has ~54.9 mln shares outstanding for about $2.6 bln current market cap through Weds
Short interest in QURE shares had nearly tripled from beginning of 2025 to about 9.7 mln shares in mid-Aug. As of Sept 25, about 8.3 mln shares were sold short, ~16% of the public float, per LSEG data (Lance Tupper is a Reuters market analyst. The views expressed are his own)
